EP1240172B1 - New aminopropylphosphinic acids - Google Patents

New aminopropylphosphinic acids Download PDF

Info

Publication number
EP1240172B1
EP1240172B1 EP00983634A EP00983634A EP1240172B1 EP 1240172 B1 EP1240172 B1 EP 1240172B1 EP 00983634 A EP00983634 A EP 00983634A EP 00983634 A EP00983634 A EP 00983634A EP 1240172 B1 EP1240172 B1 EP 1240172B1
Authority
EP
European Patent Office
Prior art keywords
compound according
amino
formula
phosphinic acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00983634A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1240172A1 (en
Inventor
Thomas Elebring
Peter Albany Molecular Research Inc. GUZZO
Marianne Swanson
Sverker Von Unge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0003640A external-priority patent/SE0003640D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to EP04021533A priority Critical patent/EP1484333A1/en
Priority to SI200030561T priority patent/SI1240172T1/xx
Publication of EP1240172A1 publication Critical patent/EP1240172A1/en
Application granted granted Critical
Publication of EP1240172B1 publication Critical patent/EP1240172B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/48—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof
    • C07F9/4808—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof the acid moiety containing a substituent or structure which is considered as characteristic
    • C07F9/4816—Acyclic saturated acids or derivatices which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention is related to novel compounds having affinity to one or more GABA B receptors, as well as to their pharmaceutically acceptable salts, solvates and stereoisomers.
  • the invention is also related to processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.
  • Gastro-oesophageal reflux disease is the most prevalent upper gastrointestinal tract disease. Current therapy has aimed at reducing gastric acid secretion, or at reducing oesophageal acid exposure by enhancing oesophageal clearance, lower oesophageal sphincter tone and gastric emptying. The major mechanism behind reflux has earlier been considered to depend on a hypotonic lower oesophageal sphincter. However recent research (e.g. Holloway & Dent (1990) Gastroenterol. Clin. N. Amer.
  • TLOSR transient lower oesophageal sphincter relaxations
  • compositions comprising a local anaesthetic, adapted to inhibit relaxation of the lower oesophageal sphicter are disclosed in WO 87/04077 and in US 5,036,057.
  • GABA B -receptor agonists have been shown to inhibit TLOSR which is disclosed in WO 98/11885.
  • GABA (4-aminobutanoic acid) is an endogenous neurotransmitter in the central and peripheral nervous systems.
  • Receptors for GABA have traditionally been divided into GABA A and GABA B receptor subtypes.
  • GABA B receptors belong to the superfamily of G-protein coupled receptors.
  • GABA B receptor agonists are being described as being of use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome (IBS) and as prokinetic and anti-tussive agents.
  • GABA B receptor agonists have also been disclosed as useful in the treatment of emesis (WO 96/11680) and recently, as mentioned above, in the inhibition of TLOSR (WO 98/11885).
  • baclofen (4-amino-3-(chlorophenyl)butanoic acid) disclosed in the Swiss patent No. CH 449, 046.
  • Baclofen has for several years been used as an antispastic agent.
  • EP 0356128 describes the use of the specific compound (3-aminopropyl)methylphosphinic acid, as a potent GABA B receptor agonist, in therapy.
  • EP 0181833 discloses substituted 3-aminopropylphosphinic acids which are found to have very high affinities towards GABA B receptor sites. In analogy to baclofen, the compounds can be used as for instance muscle relaxants.
  • EP 0399949 discloses derivatives of (3-aminopropyl)methylphosphinic acid which are described as potent GABA B receptor agonists. These compounds are stated to be useful as muscle relaxants.
  • EP 0463969 and FR 2722192 are both applications related to 4-aminobutanoic acid derivatives having different heterocyclic substituents at the 3-carbon of the butyl chain. Structure-activity relationships of several phosphinic acid analogues with respect to their affinities to the GABA B receptor as well as their muscle relaxant effect are discussed in J. Med. Chem. (1995), 38, 3297-3312. The conclusion in said article is that considerably stronger muscle relaxation could be achieved with the (S)-enantiomer of 3-amino-2-hydroxypropylmethylphosphinic acid than with baclofen and without the occurrence of unwanted CNS effects.
  • phosphinic acids having a hydrogen atom attached to phosphorous also are named phosphonous acids. These are two names for the same compounds and both names can be used. However, we have chosen to use the name phosphinic acids for the compounds according to the present invention.
  • the present invention provides novel compounds of the formula I wherein R 1 represents hydrogen, R 2 represents hydroxy, fluoro or an oxo group; R 3 represents hydrogen R 4 represents hydrogen, and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, with the exception of:
  • Even more preferred compounds are (3-amino-2-fluoropropyl)phosphinic acid, (2R)-(3-amino-2-fluoropropyl)phosphinic acid, (2 S )-(3-amino-2-fluoropropyl)phoxphinic acid, (3-amino-2-oxopropyl)phosphinic acid, (2 S )-(3-amino-2-hydroxypropyl)phosphinic acid, ) and (2 R )-(3-amino-2-hydroxypropyl)phosphinic acid.
  • R 2 is an oxo group the bond between R 2 and the carbon is a double bond.
  • the compounds according to formula I of the invention are of amphoteric nature and may be presented in the form of internal salts. They can also form acid addition salts and salts with bases. Such salts are particularly pharmaceutically acceptable acid addition salts, as well as pharmaceutically acceptable salts formed with bases. Suitable acids for the formation of such salts include, for example, mineral acids such as hydrochloric, hydrobromic, sulfuric, or phosphoric acid or organic acids such as sulfonic acids and carboxylic acids.
  • Salts with bases are, for example, alkali metal salts, e.g. sodium or potassium salts, or alkaline earth metal salts, e.g. calcium or magnesium salts, as well as ammonium salts, such as those with ammonia or organic amines.
  • the salts may be prepared by conventional methods.
  • the compounds according to formula I can be in the form of a stereoisomeric mixture, i.e. a mixture of diastereomers and/or racemates, or in the form of the single stereoisomers, i.e. the single enantiomer and/or diastereomer.
  • the compounds can also be in the form of solvates, e.g. hydrates.
  • All of the compounds according to the formula I can be used for the inhibition of TLOSR, and thus for the treatment of gastro-oesophageal reflux disease.
  • the said inhibition of TLOSR also implies that the said compounds of formula I can be used for the treatment of regurgitation in infants. Effective management of regurgitation in infants would be an important way of managing failure to thrive due to excessive loss of ingested nutrient.
  • the novel compounds can be used for the treatment of GORD-related or non-GORD related asthma, belching, coughing, pain, cocaine addiction, hiccups, IBS, dyspepsia, emesis and nociception.
  • the compounds according to the invention have surprisingly high metabolic stability in spite of the presence of a P-H bond.
  • the compounds also possess a surprisingly high therapeutic index.
  • the compounds according to formula I of the present invention may be prepared by one of the following methods.
  • R 1 and R 3 are as defined above in formula I
  • X is hydrogen or a protecting group such as -CCH 3 (OCH 2 CH 3 ) 2
  • Z is a protecting group such as t-butyloxycarbonyl
  • Y is hydrogen or a protecting group such as lower alkyl
  • compound of formula II may have been synthesized by a condensation reaction according to Scheme 1 employing an appropriate N-protected amino acid ester in which R 3 is as defined above
  • W is a protecting group such as lower alkyl and Z is as defined in formula II
  • R 1 , and R 3 are as defined above in formula I
  • X is hydrogen or a protecting group such as -CCH 3 (OCH 2 CH 3 ) 2
  • T is a group that can be converted to a-NH 2 group
  • Y is hydrogen or a protecting group such as lower alkyl
  • compound of formula VI may have been synthesized by a condensation reaction according to Scheme 2 employing an 2,3-epoxypropyl derivative, such as an appropriate N-protected 2,3-epoxypropylamine derivative or an epichlorohydrin derivative, in which R 1 and R 3 is as defined above in formula I, and a suitable protected phosphinic acid derivative activated by O-silylation, in which X and Y are as defined in formula VI, and a Lewis acid such as anhydrous ZnCl 2 , is
  • R 1 is as defined above in formula I
  • X is hydrogen or a protecting group such as -CCH 3 (OCH 2 CH 3 ) 2
  • U is an electron-withdrawing group, such as for instance -CN or -CO 2 Et which can be converted to a -CH 2 NH 2 group
  • Y is hydrogen or a protecting group such as lower alkyl
  • Halo is a halogen atom, which compound of formula VII may have been synthesized by an addition reaction according to Scheme 3 employing an unsaturated compound in which R 1 is as defined above in formula I, U and halo are as defined in formula VII, and a suitable protected phosphinic acid derivative activated by O-silylation, in which X and Y are as defined in formula VII, is converted by a reaction where the U group is being converted to -NHR 4 wherein R 4 is as defined above in formula I, and a hydrolytic reaction to obtain a compound of formula VIII wherein R 1 and R 4 are as defined above in formula I and Halo is
  • R 1 , R 3 and R 4 are as defined in formula I
  • Z is a protecting group such as t-butyloxycarbonyl
  • Halo is a halogen atom
  • compound of formula IX may have been synthesized by a substitution reaction according to Scheme 4 employing an electrophilic compound in which R 1 , R 3 and R 4 are as defined above, L is a leaving group such as iodo, Z and Halo are as defined above, and phosphinic acid activated by Osilylation, is converted by a hydrolytic reaction to a compound of formula V wherein R 1 , R 3 and R 4 are as defined above in formula I, and optionally convert the above resulting compound V into another chemical compound of the formula V and/or sepatate a resulting mixture of isomers into the individual isomers and/or convert a resulting salt into the free compound of the formula V and/or into another salt and/or convert a resulting free compound of the formula V into a salt to correspond to the above definition; or
  • R 1 , R 3 and R 4 are as defined above in formula I
  • X is hydrogen or a protecting group such as -CCH 3 (OCH 2 CH 3 ) 2
  • Y is hydrogen or a protecting group such as lower alkyl
  • compound of formula XI may have been synthesized by an addition reaction according to Scheme 4 treating an unsaturated phosphinic acid derivative, in which R 1 , R 3 and R 4 are as defined in above in formula I, with H 2 S, a mercaptide ion (HS - ) or a protected mercapto compound such as benzyl thiol in which case the protective group thereafter is removed is converted by a hydrolytic reaction to obtain a compound of formula XII, in which R 1 , R 3 and R 4 are as defined above in formula I, and optionally convert the above resulting compound XII into another chemical compound of the formula XII and/or sepatate a resulting mixture of isomers into the individual isomers and/or convert
  • the ion exchange resin was pre-washed with 2:1 methanol/water (400 mL).
  • the crude product dissolved in 1:1 methanol/water was loaded onto the column and washed with 1: 1 methanol/water (400 mL).
  • the eluent was changed to 3:1 methanol/concentrated ammonium hydroxide.
  • Two fractions (150 mL totally) were combined and evaporated to give 645 mg (34%) of (3-amino-2-fluoropropyl)phosphinic acid as a white solid.
  • Ammonium hypophosphite (73.8 g, 0.89 mol) was added to 3 necked 2-L flask equipped with a mechanical stirrer, thermometer, addition funnel and an argon bubbler. The flask was placed in a water bath at room temperature and N,O- Bis -(trimethylsilyl)acetamide (215 mL, 0.87 mol -BSA) was added at such a rate that the internal temperature was maintained below 38 °C (30 minutes approx.) using ice cooling. Upon completing the addition of BSA, the reaction mixture was heated to 45-48 °C and maintained at this temperature for 1h.
  • the reaction was cooled to room temperature and a solution of tert -butyl (2 R )-2-fluoro-3-iodopropylcarbamate (27.3 g, 0.09 mol) in methylene chloride (300 mL) was added to the reaction mixture. The reaction was then allowed to stir at room temperature for 18 h. The reaction mixture was cooled to 0 °C and was cautiously quenched with methanol (275 mL) and then with water (32 mL). The reaction mixture was stirred for 30 min after which the reaction was filtered and the solids were washed with methanol. The filtrate was concentrated and the residue placed under high vacuum (0.1 mm Hg) overnight.
  • the crude residue was triturated with methylene chloride, methanol, concentrated ammonium hydroxide solution (80:20:1) and was filtered. The filtrate was concentrated under reduced pressure and the trituration was repeated.
  • the crude concentrate was transferred to a 2-L flask, dissolved in methanol (375 mL) and placed in a water bath at room temperature. A saturated solution of hydrogen chloride gas in ethyl acetate (500 mL) was added and the mixture stirred for 3 h. The reaction mixture was filtered and the solids were washed with a mixture of methanol and ethyl acetate (90:10).
  • Ammonium hypophosphite (58.1 g, 0.70 mol) was added to a 3 necked 2-L flask equipped with a mechanical stirrer, thermometer, addition funnel and an argon bubbler.
  • N,O- Bis -(trimethylsilyl)acetamide (175.9 mL, 0.71 mol -BSA) was added at such a rate that the internal temperature was maintained between 35-40 °C.
  • BSA Upon completing the addition of BSA, the reaction mixture was maintained at 35-40 °C for 45 min.
  • Methylene chloride 150 mL was added and the mixture was stirred at 35-40 °C for an additional 45 min.
  • the reaction was cooled to room temperature and a solution of tert -butyl (2 S )-2-fluoro-3-iodopropylcarbamate (42.5 g, 0.14 mol) in methylene chloride (300 mL) was added to the reaction mixture. The reaction was then allowed to stir at room temperature overnight. The reaction mixture was cooled to 0 °C and was cautiously quenched with methanol (150 mL) and then with water (60 mL). The reaction was concentrated and the residue placed under high vacuum (0.1 mm Hg). The residue was adjusted to approximately pH 8 by the addition of concentrated ammonium hydroxide (50 mL) then methylene chloride (400 mL) and methanol (250 mL) were added.
  • concentrated ammonium hydroxide 50 mL
  • methylene chloride 400 mL
  • methanol 250 mL
  • Example I Ethyl 3-[(diethoxymethyl)(ethoxy)phosphoryl]-2-fluoropropanoate (intermediate to the compound according to Example 1)
  • Example I3 Ethyl (2 R )-(3-chloro-2-hydroxypropyl)(1,1-diethoxyethyl)phosphinate (intermediate to the compound according to Example 2)
  • Example I Ethyl (2 S )-(3-amino-2-hydroxypropyl)(1,1-diethoxyethyl)phosphinate (intermediate to the compound according to Example 2)
  • aqueous layer was pH adjusted by the addition of a few mL of 10% aqueous Na 2 CO 3 and repeatedly extracted with methylene chloride. The combined organic layers were dried over Na 2 SO 4 and evaporated to give 1.2 g (26%) of ethyl (2 S )-(3-amino-2-hydroxypropyl)(1,1-diethoxyethyl)phosphinate as a clear oil.
  • Example I5. Ethyl (2 S )-(3-chloro-2-hydroxypropyl)(1,1-diethoxyethyl)phosphinate (intermediate to the compound according to Example 3)
  • Example I6 Ethyl (2 R )-(3-amino-2-hydroxypropyl)(1,1-diethoxyethyl)phosphinate (intermediate to the compound according to Example 3)
  • aqueous layer was pH adjusted by the addition of a few mL of 10% aqueous Na 2 CO 3 and repeatedly extracted with methylene chloride. The combined organic layers were dried over Na 2 SO 4 and evaporated to give 0.9 g (19%) of ethyl (2 R )-(3-amino-2-hydroxypropyl)(1,1-diethoxyethyl)phosphinate as a clear oil.
  • Example I7 Ethyl [3-[N-(tert-butoxycarbonyl)amino]-2-oxopropyl](1,1-diethoxyethyl)phosphinate (intermediate to the compound according to the Example 4)
  • Example I8 (2 R )-3-(Dibenzylamino)-2-fluoro-1-propanol (intermediate to the compound according to the Example 5)
  • Lithium borohydride (5.3 g, 0.24 mol) was suspended in THF (200 mL) under a nitrogen atmosphere and cooled to -15°C with stirring.
  • Methyl (2 R )-3-(dibenzylamino)-2-fluoropropanoate (56.6 g, 0.19 mol) was suspended in THF (250 mL) and added dropwise to the mixture over 1 h; the internal temperature was maintained below -10 °C during the addition. On completion of addition, the reaction mixture was allowed to warm to room temperature and stirred at this temperature for 17 h. The reaction mixture was cooled to 0 °C and cautiously quenched with a saturated aqueous solution of ammonium chloride (300 mL).
  • reaction mixture was extracted with ethyl acetate (2 x 200 mL) and the organic phase was concentrated under reduced pressure.
  • Example I10 Tert -butyl (2 R )-2-fluoro-3-hydroxypropylcarbamate (intermediate to the compound according to the Example 5)
  • Example I11 Tert -butyl (2 R )-2-fluoro-3-iodopropylcarbamate (intermediate to the compound according to the Example 5)
  • Imidazole (26.6 g, 0.39 mol) was dissolved in methylene chloride (400 mL) at room temperature.
  • Iodine (102.5 g, 0.39 mol) was added and the reaction mixture was stirred for 10 min at room temperature and then cooled to 0 °C.
  • Triphenylphosphine (102.5 g, 0.39 mol) was added portionwise over 10 min such that the internal temperature remained below 10 °C.
  • a solution of tert -butyl (2 R )-2-fluoro-3-hydroxypropylcarbamate (60.4 g, 0.31 mol) in methylene chloride (100 mL) was added dropwise.
  • tert -butyl (2 R )-2-fluoro-3-hydroxypropylcarbamate On completion of addition of tert -butyl (2 R )-2-fluoro-3-hydroxypropylcarbamate, additional methylene chloride (200 mL) was added. The reaction mixture was allowed to warm to room temperature and stirring was continued for 17 h. The reaction mixture was filtered through a pad of Celite® (50 g) and washed with additional methylene chloride. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography eluting with methylene chloride. This procedure afforded tert -butyl (2 R )-2-fluoro-3-iodopropylcarbamate as a white solid (64.7 g, 68%).
  • Example I13 (2 S )-3-(Dibenzylamino)-2-fluoro-1-propanol (intermediate to the compound according to the Example 6)
  • Example I15 Tert -butyl (2 S )-2-fluoro-3-hydroxypropylcarbamate (intermediate to the compound according to the Example 6
  • Example I16 Tert -butyl (2 S )-2-fluoro-3-iodopropylcarbamate (intermediate to the compound according to the Example 6)
  • Imidazole (19.8 g, 0.29 mol) was dissolved in methylene chloride (900 mL) at room temperature. Iodine (73.9 g, 0.29 mol) was added and the reaction mixture was stirred for 10 min at room temperature and then cooled to 0 °C. Triphenylphosphine (76.3 g, 0.29 mol) was added portionwise over 10 min such that the internal temperature remained below 10 °C. A solution of tert -butyl (2 S )-2-fluoro-3-hydroxypropylcarbamate (45.0 g, 0.23 mol) in methylene chloride (300 mL) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirring was continued for 12 h.
  • the compound according to formula I of the present invention can be used as an active ingredient in a pharmaceutical preparation for oral, rectal, epidural, intravenous, intramuscular, subcutanous, nasal administration and administration by infusion or for any other suitable route of administration.
  • a pharmaceutical preparation for oral, rectal, epidural, intravenous, intramuscular, subcutanous, nasal administration and administration by infusion or for any other suitable route of administration.
  • the way of administration is oral or by injection/infusion.
  • the pharmaceutical preparations contain a compound of the present invention in combination with one or more pharmaceutically acceptable ingredients.
  • the finished dosage forms are manufactured by known pharmaceutical processes.
  • the amount of active compounds is between 0.1-95% by weight of the preparation, preferably between 0.2-20% by weight in preparations for parenteral use and preferably between 1-50% by weight in preparations for oral administration.
  • the compound selected may be mixed with solid pharmaceutically acceptable ingredients (among these for instance disintegrating agents and lubricating agents). The mixture is then processed into granules, tablets, capsules or sachets.
  • Dosage units for rectal administration may be prepared in the form of suppositories; in the form of a gelatine rectal capsule; in the form of a ready-made micro enema; or in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
  • Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, or in the form of a dry mixture to be reconstituted with a suitable solvent prior to use.
  • Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent and are dispensed into ampoules or vials. They may also be prepared as a dry preparation to by reconstituted with a suitable solvent extemporaneously before use.
  • the typical daily dose of the active compound will depend on various factors such as for example the individal requirement of each patient, the route of administration and the disease. In general, dosages will be in the range of 1 ⁇ g to 100 mg per day and kg body weight, preferably 10 ⁇ g to 20 mg per day and kg body weight.
  • Rat synaptic membranes were prepared from the whole brain of Sprague Dawley male rats essentially as described previously (Zukin, et al. (1974) Proc. Natl. Acad. USA 71, 4802-4807).
  • TCI Tris Calcium Isoguvacine
  • Tris Tri(hydroxymethyl)aminomethane
  • pH 7.4 2.5 mM CaCl 2
  • 40 ⁇ M isoguvacine 20 nM [ 3 H]GABA (specific activity: 3 Tera Becquerel (TBq)/mmol)
  • test compound or solvent 80 ⁇ g synaptic membrane protein using 96-well plates.
  • the compounds of the present invention were found to have high affinities and potencies for the GABA B receptor as revealed by low IC 50 and EC 50 in the binding and ileum assays, respectively.
  • the compounds have also been found to reduce TLOSR when administered i.v. as well as p.o. in animal models. Contrary to what has been claimed in the literature for 3-aminopropylphosphinic acid derivatives having a P-H bond, we found that the compounds of the present invention have high metabolic stability in animal models.
  • CNS side-effects (as measured by reduction in body temperature in the mouse) were not observable or only seen at very high doses. Therefore, the difference between therapeutic dose (inhibition of TLOSR in the dog model) and dose causing side-effects (in the mouse model) was unexpectedly high.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP00983634A 1999-12-09 2000-12-04 New aminopropylphosphinic acids Expired - Lifetime EP1240172B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04021533A EP1484333A1 (en) 1999-12-09 2000-12-04 New aminopropylphosphonous acids
SI200030561T SI1240172T1 (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9904508A SE9904508D0 (sv) 1999-12-09 1999-12-09 New compounds
SE9904508 1999-12-09
SE0003640A SE0003640D0 (sv) 2000-10-09 2000-10-09 New compounds
SE0003640 2000-10-09
PCT/SE2000/002426 WO2001042252A1 (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP04021533A Division EP1484333A1 (en) 1999-12-09 2000-12-04 New aminopropylphosphonous acids

Publications (2)

Publication Number Publication Date
EP1240172A1 EP1240172A1 (en) 2002-09-18
EP1240172B1 true EP1240172B1 (en) 2004-11-10

Family

ID=26655259

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00983634A Expired - Lifetime EP1240172B1 (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids
EP04021533A Withdrawn EP1484333A1 (en) 1999-12-09 2000-12-04 New aminopropylphosphonous acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04021533A Withdrawn EP1484333A1 (en) 1999-12-09 2000-12-04 New aminopropylphosphonous acids

Country Status (33)

Country Link
US (5) US6576626B2 (enExample)
EP (2) EP1240172B1 (enExample)
JP (2) JP3914435B2 (enExample)
KR (1) KR100689144B1 (enExample)
CN (1) CN1198832C (enExample)
AR (1) AR030541A1 (enExample)
AT (1) ATE282043T1 (enExample)
AU (1) AU780459B2 (enExample)
BR (1) BR0016253A (enExample)
CA (1) CA2397583C (enExample)
CZ (1) CZ20021983A3 (enExample)
DE (1) DE60015796T2 (enExample)
DK (1) DK1240172T3 (enExample)
EE (1) EE05067B1 (enExample)
ES (1) ES2230174T3 (enExample)
HK (1) HK1048321B (enExample)
HU (1) HUP0300301A3 (enExample)
IL (2) IL149840A0 (enExample)
IS (1) IS2231B (enExample)
MX (1) MXPA02005536A (enExample)
MY (1) MY125414A (enExample)
NO (1) NO329595B1 (enExample)
NZ (1) NZ519376A (enExample)
PL (1) PL201789B1 (enExample)
PT (1) PT1240172E (enExample)
RU (1) RU2260595C2 (enExample)
SE (1) SE9904508D0 (enExample)
SI (1) SI1240172T1 (enExample)
SK (1) SK286904B6 (enExample)
TW (1) TWI228510B (enExample)
UA (1) UA71649C2 (enExample)
WO (1) WO2001042252A1 (enExample)
ZA (1) ZA200204127B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
US20040063684A1 (en) * 2001-02-05 2004-04-01 Kamm Michael A. Treatment of oesophageal motility disorders and gastro-oesophageal reflux disease
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
SE0402462D0 (sv) * 2004-10-08 2004-10-08 Astrazeneca Ab New process
WO2006050471A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US20060160777A1 (en) * 2004-12-27 2006-07-20 Anders Lehmann New use of GABAbeta receptor agonists
JP2009521430A (ja) 2005-12-23 2009-06-04 アストラゼネカ・アクチエボラーグ Ｇａｂａ−ｂ受容体モジュレーター
EP1966154A4 (en) 2005-12-23 2011-01-26 Astrazeneca Ab IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
ES2373255T3 (es) * 2007-05-04 2012-02-01 Astrazeneca Ab Proceso para s�?ntesis de �?cidos alquilfosf�?nicos mediante iniciación de una amina y un aminóxido.
JP2010534239A (ja) * 2007-07-25 2010-11-04 アストラゼネカ・アクチエボラーグ Ｎｅｒｄの治療のための（３−アミノ−２−フルオロプロピル）ホスフィン酸の使用
WO2009082344A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel process for making (2r)-(3-amino-2-fluoropropyl)phosphinic acid form a
EP2235027A4 (en) * 2007-12-21 2011-06-22 Astrazeneca Ab NEW CRYSTALLINE FORM OF (2R) - (3-AMINO-2-FLUOROPROPYL) PHOSPHINIC ACID
WO2009082348A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel crystalline form c of (2r)-(3-amino-2-fluoropropyl)phosphinic acid
WO2009145716A1 (en) * 2008-05-28 2009-12-03 Astrazeneca Ab New pharmaceutical formulation useful in gerd therapy
CN102177164B (zh) 2008-11-05 2015-02-11 科莱恩金融(Bvi)有限公司 利用烯丙醇/丙烯醛制备二烷基次膦酸、二烷基次膦酸酯和二烷基次膦酸盐的方法,以及它们的用途
EP2352740B1 (de) 2008-11-07 2014-09-24 Clariant Finance (BVI) Limited Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
JP5743219B2 (ja) 2008-11-11 2015-07-01 クラリアント・ファイナンス・（ビーブイアイ）・リミテッド アリル化合物を用いる、モノアリル官能性ジアルキルホスフィン酸、それらの塩およびエステルの製造方法およびそれらの使用
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
KR101697948B1 (ko) 2008-12-18 2017-01-19 클라리언트 파이넌스 (비브이아이)리미티드 아세틸렌을 사용하는 에틸렌디알킬포스핀산, 에틸렌디알킬포스핀산 에스테르 및 에틸렌디알킬포스핀산 염의 제조방법 및 이의 용도
DE102008063642A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
DE102008063627A1 (de) * 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449046A (de) 1963-07-09 1967-12-31 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
GB8425872D0 (en) * 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
WO1987004077A1 (en) 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
US4740332A (en) * 1986-05-12 1988-04-26 E. R. Squibb & Sons, Inc. Process for preparing phosphonous acids
GB8820266D0 (en) * 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
US5281747A (en) 1989-05-13 1994-01-25 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
US5567840A (en) 1989-05-13 1996-10-22 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
US5006560A (en) 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
IL114631A (en) * 1990-06-22 1998-12-06 Novartis Ag Anti-epileptic compositions containing gabab- antagonistic compounds
FR2663934B1 (fr) 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
AU662404B2 (en) * 1992-05-08 1995-08-31 Novartis Ag Novel N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids
FR2722192A1 (fr) 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9420784D0 (en) 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) 1996-09-18 1996-09-18 Astra Ab Medical use
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds

Also Published As

Publication number Publication date
SE9904508D0 (sv) 1999-12-09
AU780459B2 (en) 2005-03-24
WO2001042252A1 (en) 2001-06-14
AU2036401A (en) 2001-06-18
UA71649C2 (en) 2004-12-15
US20070021393A1 (en) 2007-01-25
CN1409716A (zh) 2003-04-09
HUP0300301A2 (hu) 2003-06-28
JP3914435B2 (ja) 2007-05-16
JP2003516407A (ja) 2003-05-13
NO20022728L (no) 2002-08-07
EP1240172A1 (en) 2002-09-18
HK1053125A1 (en) 2003-10-10
AR030541A1 (es) 2003-08-27
HK1048321B (en) 2005-09-30
ATE282043T1 (de) 2004-11-15
RU2260595C2 (ru) 2005-09-20
US6576626B2 (en) 2003-06-10
ZA200204127B (en) 2003-08-25
CN1198832C (zh) 2005-04-27
CZ20021983A3 (cs) 2002-11-13
TWI228510B (en) 2005-03-01
IL149840A0 (en) 2002-11-10
EP1484333A1 (en) 2004-12-08
BR0016253A (pt) 2002-08-27
US20050137414A1 (en) 2005-06-23
US20030220303A1 (en) 2003-11-27
KR20020060992A (ko) 2002-07-19
SK7642002A3 (en) 2002-12-03
US7807658B2 (en) 2010-10-05
NO329595B1 (no) 2010-11-22
PL201789B1 (pl) 2009-05-29
US6841698B2 (en) 2005-01-11
SK286904B6 (sk) 2009-07-06
IS6408A (is) 2002-06-06
CA2397583A1 (en) 2001-06-14
CA2397583C (en) 2010-11-09
MY125414A (en) 2006-07-31
EE05067B1 (et) 2008-08-15
DE60015796D1 (de) 2004-12-16
KR100689144B1 (ko) 2007-03-08
PT1240172E (pt) 2005-02-28
US20080146836A1 (en) 2008-06-19
US7034176B2 (en) 2006-04-25
EE200200286A (et) 2003-08-15
NZ519376A (en) 2003-11-28
JP2006306885A (ja) 2006-11-09
PL364795A1 (en) 2004-12-13
ES2230174T3 (es) 2005-05-01
MXPA02005536A (es) 2004-09-10
RU2002113909A (ru) 2004-01-10
SI1240172T1 (en) 2005-02-28
IS2231B (is) 2007-04-15
US20020156053A1 (en) 2002-10-24
DE60015796T2 (de) 2005-11-03
HUP0300301A3 (en) 2008-12-29
DK1240172T3 (da) 2005-02-14
HK1048321A1 (en) 2003-03-28
NO20022728D0 (no) 2002-06-07
IL149840A (en) 2006-04-10

Similar Documents

Publication Publication Date Title
EP1240172B1 (en) New aminopropylphosphinic acids
US6596711B1 (en) (Aminopropyl)methylphosphinic acids
WO2002100871A1 (en) New compounds useful in reflux disease
HK1069584A (en) New aminopropylphosphonous acids
TW200401779A (en) New aminopropylphosphinic acids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020709

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020709;LT PAYMENT 20020709;LV PAYMENT 20020709;MK PAYMENT 20020709;RO PAYMENT 20020709;SI PAYMENT 20020709

17Q First examination report despatched

Effective date: 20030703

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GUZZO, PETERALBANY MOLECULAR RESEARCH INC.

Inventor name: ELEBRING, THOMAS

Inventor name: VON UNGE, SVERKER

Inventor name: SWANSON, MARIANNE

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60015796

Country of ref document: DE

Date of ref document: 20041216

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20050104

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20050400507

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2230174

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1048321

Country of ref document: HK

ET Fr: translation filed
26N No opposition filed

Effective date: 20050811

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20101122

Year of fee payment: 11

Ref country code: DK

Payment date: 20101123

Year of fee payment: 11

Ref country code: IE

Payment date: 20101126

Year of fee payment: 11

Ref country code: MC

Payment date: 20101129

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20101126

Year of fee payment: 11

Ref country code: LU

Payment date: 20101216

Year of fee payment: 11

Ref country code: FI

Payment date: 20101203

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20101129

Year of fee payment: 11

Ref country code: GR

Payment date: 20101126

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20101118

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20101213

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20111220

Year of fee payment: 12

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20120604

BERE Be: lapsed

Owner name: *ASTRAZENECA A.B.

Effective date: 20111231

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

LTIE Lt: invalidation of european patent or patent extension
LTLA Lt: lapse of european patent or patent extension

Effective date: 20111204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111204

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120604

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20120709

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20050400507

Country of ref document: GR

Effective date: 20120704

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111204

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120704

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 282043

Country of ref document: AT

Kind code of ref document: T

Effective date: 20111204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120102

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111204

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20121128

Year of fee payment: 13

Ref country code: CH

Payment date: 20121213

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20121128

Year of fee payment: 13

Ref country code: SE

Payment date: 20121217

Year of fee payment: 13

Ref country code: ES

Payment date: 20121227

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20130107

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111204

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20130701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121204

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20131107

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60015796

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20131204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131205

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60015796

Country of ref document: DE

Effective date: 20140701

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131231

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131231

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131204

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141204